These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 20157197

  • 1. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus.
    Bajaj M, Baig R, Suraamornkul S, Hardies LJ, Coletta DK, Cline GW, Monroy A, Koul S, Sriwijitkamol A, Musi N, Shulman GI, DeFronzo RA.
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1916-23. PubMed ID: 20157197
    [Abstract] [Full Text] [Related]

  • 2. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [Abstract] [Full Text] [Related]

  • 3. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
    Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.
    Diabetes; 2003 Jun; 52(6):1364-70. PubMed ID: 12765945
    [Abstract] [Full Text] [Related]

  • 4. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [Abstract] [Full Text] [Related]

  • 5. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [Abstract] [Full Text] [Related]

  • 6. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial.
    Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, Prentki M, Madiraju M, Jenkinson CP, Cersosimo E, Musi N, Defronzo RA.
    Diabetologia; 2009 Apr; 52(4):723-32. PubMed ID: 19169664
    [Abstract] [Full Text] [Related]

  • 7. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
    Ravikumar B, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.
    Diabetes; 2008 Sep; 57(9):2288-95. PubMed ID: 18535187
    [Abstract] [Full Text] [Related]

  • 8. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA.
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
    [Abstract] [Full Text] [Related]

  • 9. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
    Phielix E, Brehm A, Bernroider E, Krssak M, Anderwald CH, Krebs M, Schmid AI, Nowotny P, Roden M.
    Diabetes Obes Metab; 2013 Oct; 15(10):915-22. PubMed ID: 23574533
    [Abstract] [Full Text] [Related]

  • 10. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.
    Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA.
    Int J Obes Relat Metab Disord; 2004 Jun; 28(6):783-9. PubMed ID: 15024400
    [Abstract] [Full Text] [Related]

  • 11. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA.
    Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
    [Abstract] [Full Text] [Related]

  • 12. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
    Teranishi T, Ohara T, Maeda K, Zenibayashi M, Kouyama K, Hirota Y, Kawamitsu H, Fujii M, Sugimura K, Kasuga M.
    Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
    [Abstract] [Full Text] [Related]

  • 13. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
    Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M.
    Obesity (Silver Spring); 2011 Dec; 19(12):2310-5. PubMed ID: 21660077
    [Abstract] [Full Text] [Related]

  • 14. Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance.
    Serlie MJ, Allick G, Groener JE, Ackermans MT, Heijligenberg R, Voermans BC, Aerts JM, Meijer AJ, Sauerwein HP.
    J Clin Endocrinol Metab; 2007 Jan; 92(1):166-71. PubMed ID: 17062758
    [Abstract] [Full Text] [Related]

  • 15. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
    Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K.
    Hepatology; 2009 Oct; 50(4):1087-93. PubMed ID: 19670459
    [Abstract] [Full Text] [Related]

  • 16. Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function.
    Bajpeyi S, Pasarica M, Conley KE, Newcomer BR, Jubrias SA, Gamboa C, Murray K, Sereda O, Sparks LM, Smith SR.
    Metabolism; 2017 Apr; 69():24-32. PubMed ID: 28285649
    [Abstract] [Full Text] [Related]

  • 17. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.
    Yamasaki Y, Kawamori R, Wasada T, Sato A, Omori Y, Eguchi H, Tominaga M, Sasaki H, Ikeda M, Kubota M, Ishida Y, Hozumi T, Baba S, Uehara M, Shichiri M, Kaneko T.
    Tohoku J Exp Med; 1997 Nov; 183(3):173-83. PubMed ID: 9550126
    [Abstract] [Full Text] [Related]

  • 18. Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
    Joya-Galeana J, Fernandez M, Cervera A, Reyna S, Ghosh S, Triplitt C, Musi N, DeFronzo RA, Cersosimo E.
    Diabetes Metab Res Rev; 2011 May; 27(4):373-82. PubMed ID: 21309063
    [Abstract] [Full Text] [Related]

  • 19. Diabetes mellitus is associated with increased intramyocellular triglyceride, but not diglyceride, content in obese humans.
    Anastasiou CA, Kavouras SA, Lentzas Y, Gova A, Sidossis LS, Melidonis A.
    Metabolism; 2009 Nov; 58(11):1636-42. PubMed ID: 19615699
    [Abstract] [Full Text] [Related]

  • 20. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
    Miyazaki Y, He H, Mandarino LJ, DeFronzo RA.
    Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.